COGNITION THERAPEUTICS INC
CGTXDrugs in Pipeline
5
Phase 3 Programs
0
Upcoming Catalysts
3
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
CGTX Earnings Report
EPS Est: $-0.06 | FQ end 2026-06
2 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How CGTX's past catalysts played out
CT1812
Early Alzheimer's Disease
C105
Cognition Disorders
golexanolone
Primary Biliary Cholangitis (PBC)
Active Treatment- CT1812 100 mg
Alzheimer Disease
Dexmedetomidine
Alzheimer Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CT1812 | Phase 2 | Early Alzheimer's Disease | - | - |
C105 | Phase 2 | Cognition Disorders | - | - |
golexanolone | Phase 2 | Primary Biliary Cholangitis (PBC) | - | - |
Active Treatment- CT1812 100 mg | Phase 2 | Alzheimer Disease | - | - |
Dexmedetomidine | Phase 2 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in COGNITION THERAPEUTICS INC's drug pipeline?→
CatalystAlert tracks 5 drug candidates in COGNITION THERAPEUTICS INC's (CGTX) pipeline across Phase 2. Its lead program is CT1812 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is COGNITION THERAPEUTICS INC's next FDA catalyst?→
COGNITION THERAPEUTICS INC's (CGTX) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CGTX biotech catalysts?→
Add CGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow COGNITION THERAPEUTICS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.